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Endemic in more than 90 countries and territories, malaria is the most widely, populational, and geographically, parasitic 
disease in the world. Plasmodium sp. resistance to available drugs is one of the biggest problems for malaria eradication. 
In this study, we develop a method for the simultaneous determination of two new derivatives of betulinic and ursolic acids 
with antimalarial activity designated 3-O-butanoylbetulinic and 3-O-butanoylursolic acids. An analytical method was 
developed by high-performance liquid chromatography coupled, in series, to ultraviolet (UV) and charged aerosol (CAD) 
detectors. The chromatographic system, operated isocratically by reversed-phase, consisted in a mobile phase composed 
of acetonitrile: water pH 3.0 adjusted with formic acid (85:15, v/v), flow rate of 1.2 mL/min and a PhenoSphere Next 
octadecylsilane column (250 mm x 4.6 mm, 5 μm particle size). Chromatograms were recorded simultaneously in UV and 
CAD, at a concentration of 50 µg mL-1, an injection volume of 20 μL at a controlled temperature of 50 °C. The method 
was found to be selective, linear (r > 0.99), precise (RSD < 2.0%), accurate, and robust for both analytes, and considered 
statistically validated, and can be applied to the identification and quantification of these new drug candidates. 
 






Malaria is considered one of the greatest challenges of the 
21st century. In 2018, an estimated 228 million cases of 
malaria occurred worldwide, reported by 91 countries and 
territories, compared with 231 million cases in 2017. In 
the same year, an estimated US$ 2.7 billion was invested 
around the world in malaria control and elimination by 
governments of malaria endemic countries [1].  
The pathology, caused by several protozoa of the genus 
Plasmodium sp., has vectoral transmission by mosquitoes 
Anopheles sp., which contribute to the broad geographic 
distribution and the difficulty of controlling the disease 
[2]. Furthermore, the resistance of the plasmodium to the 
current drugs is a major problem in the eradication of 
malaria. In the 1950s, resistance to chloroquine, the most 
widely used drug, was detected in South Asia and South 
America for the first time. In 10 years, the problem was 
observed in the African continent [3]. Recently, there was 
a rapid worldwide increase in the resistance of P. 
falciparum, the most virulent species, to the drug [4] with 
children from 1 to 5 years having the highest incidence 
and mortality [1].  
Betulinic acid (BA) is a naturally occurring pentacyclic 
lupane-like triterpene distributed in the Kingdom Plantae 
[5]. Several biological activities for BA and its derivatives 
have been discovered and studied. These include 
antimalarial [6,7], anti-HIV [8-10], antineoplastic [11], 
antibacterial [12,13] and antileishmanicidal [14], among 
others. Ursolic acid (UA) is a triterpenic secondary 
metabolite with several known activities, such as 
antimalarial [15], anticancer [16], anti-inflammatory [17] 
and antioxidant [18]. In this context, Silva et al. developed 
a semi-synthesis method to a series of betulinic and 
ursolic acid analogues aiming to improve the therapeutic 
activity and reduce toxicity of such molecules. The study 
investigates carbon-3 esterification, resulting in two non-
cytotoxic, short side acyl chain compounds (Fig. 1), 
designated 3-O-butanoylbetulinic acid (3-OBB) and 3-O-
butanoylursolic acid (3-OBU), presenting anti-malarial 
activity against chloroquine-sensitive P. falciparum 3D7 
up to five times higher (IC50 of 5 ± 0,14 µm and 7 ± 0,15 
µm, respectively) than its precursors, BA and UA [7].  
 
 
Figure 1. Chemical structures of 3-O-butanoylbetulinic acid and 
3-O-butanoylursolic acid. 
 




Quality control of anti-malarial drugs is very important to 
assure treatment efficacy and to avoid the development of 
resistance [19]. However, there are no reported methods 
regarding the identification and quantitation of 3-OBB 
and 3-OBU. Hence, in this study, a simple and sensitive 
reversed-phase high-performance liquid chromatography 
method coupled, in line, to ultraviolet and charged aerosol 
detectors (RP-HPLC-UV-CAD) for the simultaneous 
determination of these molecules was developed and 
validated. Beyond the usual UV detection, charged 
aerosol detection was chosen because it is considered a 
universal detector for nonvolatile analytes and has a 
response independent of chemical properties [20], 
characteristics that work in favor of low ultraviolet 
absorptive molecules like 3-OBB and 3-OBU and their 
impurities. In addition, CAD was used to identify non-
chromophore organic impurities in mass balance. The 
developed method can be applied in further studies with 
these drug candidates and quality control issues, such as 
the preparation of chemical reference material that will 
improve the quality of the data obtained in those studies. 




The analytical method was developed and validated in a 
Shimadzu LC system (Kyoto, Japan) equipped with a LC-
20AT gradient pump, DGU-14A vacuum degasser and 
CTO-10A column oven coupled in series with SPD-
M10A Diode Array Detector and Corona CAD (ESA 
Bioscience, Chelmsford, MA, USA). CAD detection was 
carried out using nitrogen as nebulizer gas (35 psi). 
Chromeleon 6.8 software (Dionex Corporation, 
Sunnyvale, CA, USA) and LC Solutions (Shimadzu, 
Kyoto, Japan) were used for the instrument control, data 
acquisition and analysis of the CAD and UV results, 
respectively.  
 
Chemicals and Materials 
 
BA and UA were provided by the Laboratory of 
Phytochemistry and Organic Synthesis – Federal 
University of Rio Grande do Sul, Brazil. BA and UA were 
obtained from Platanus acerifolia bark (2.0% yield) and 
industrial residue of apple peel Malus domestica (2.8% 
yield), respectively.  
Butyric anhydride, dimethylaminopyridine, pyridine and 
cyclohexane (≥99.0%, ≥99.0%, ≥99.0% and 99.5%) used 
in the semisynthesis of 3-OBB and 3-OBU acids were 
obtained from Sigma-Aldrich (Germany). 
Dichloromethane (99.5%) were purchased from VETEC 
(Rio de Janeiro, Brazil). Silica gel 60 and silica gel 60 
F254 TLC plates used during the purification of the 
compounds were purchased from Merck (Germany). 
Acetonitrile (HPLC grade) and formic acid (98%) were 
purchased from Merck (Germany). Purified water was 
produced by a Milli-Q system (Millipore Corp., MA, 
USA).  
 
Semi-synthesis of 3-OBB and 3-OBU 
 
Semi-synthesis was performed as described by Silva et al 
[7]. Butyric anhydride (1.1 mmol, 5 Eq), 4-
dimethylaminopyridine (0.22 mmol, 1 Eq) and the acid of 
interest (betulinic or ursolic) diluted in pyridine (0.22 
mmol, 1Eq) were added in a round bottom flask and 
refluxed for 1 h in a nitrogen atmosphere at room 
temperature. Purification of 3-OBB and 3-OBU were 
carried out using column chromatography. Silica gel 60 
was used as stationary phase and different proportions of 
dichloromethane and cyclohexane were used as mobile 
phase. Analytical thin layer chromatography was 
performed to identify the synthesized compounds [7]. 
Further purification was performed by recrystallization 
using 60 °C acetonitrile. 
Melting range (FP 90, Mettler Toledo, Switzerland), 
differential scanning calorimetry (DSC-60, Shimadzu, 
Japan), infrared spectroscopy (Spectrum BX, Perkin 
Elmer, USA) and nuclear magnetic resonance 
spectroscopy (NMR 1H and 13C) (DPX, Bruker, 
Germany) were used to identify and characterize the 




For the application of analytical methods, chemical 
reference standards are commonly used, comparatively, 
to identity and quantify drug content. In this case, as we 
synthesized these molecules and there is no compendial 
standard available, we decided to perform a mass balance 
to evaluate the purity of the compounds. Mass balance 
consider inorganic (residue on ignition), organic (HPLC-
UV-CAD) and volatile (loss on drying) impurities (100 - 
impurities%) (n = 3) [21]. Besides quantifying the 
compounds’ purity, mass balance offers the ability to 




LC-UV-CAD system was developed using a 
PhenoSphere Next C18 (250 x 4.6 mm, particle size 5 µm, 
Phenomenex) column at 50 °C. An isocratic elution was 
achieved by using a mobile phase consisted of 
acetonitrile:water with pH adjusted to 3.0 with formic 
acid (85: 15, v/v). The flow rate was set at 1.2 mL/min 
and injection volume was 20 µL. For UV detection, a 
wavelength of 210 nm was used. For CAD detection, 
nitrogen pressure was set at 35 psi. 3-OBU and 3-OBB 
were retained in the system for 24 and 27 minutes, 
respectively.  
 
Standard stock and working solutions 
 
Stock solutions of 3-OBB and 3-OBU were individually 
prepared by transferring 25.0 mg of each purified 
substance to a 100 mL volumetric flask. Substances were 
dissolved in 10 mL of dichloromethane and the volumes 
were completed with mobile phase to the final 
concentration of 250.0 µg/mL. The required working 
 




solutions were prepared by further dilutions in mobile 
phase. 
 
Validation of the analytical method   
 
Method validation was performed according to current 




Selectivity of the method was performed using qualitative 
individual solutions containing diluent, BA, UA, 3-OBB 
acid and 3-OBU. A solution containing all compounds, 
simultaneously, to identify the elution times and to prove 
the selectivity of the analytical method was also 
evaluated. BA and UA were chosen, as synthetic 
precursors, to ensure the method discrimination once they 
have similar chemical structure to the synthesized 3-OBB 
and 3-OBU and, therefore, this evaluation was considered 
critical to validate specificity. Peak purity was verified by 
UV-DAD detection. 
 
Linearity, LOD and LOQ 
 
The linearity of the method was verified by the 
construction of three independent calibration curves 
prepared at five concentration levels: 25.0, 37.5, 50.0, 
62.5 and 75.0 µg/mL (50% - 150% of the nominal 
concentration). Triplicate determinations at each 
concentration level were performed and concentration 
versus area values were plotted. Results were statically 
evaluated by linear regression of the mean curve (α = 
0.05), correlation coefficient (r), residue distribution and 
homoscedasticity. Limit of detection (LOD) and Limit of 
quantification (LOQ) were determined on the signal-to-
noise ratio of 3:1 and 10:1, respectively. 
 
Precision and accuracy 
 
Precision was determined by six replicates of each 
sample, prepared individually, at the concentration of 50.0 
µg/mL, in two different days (day 1 as repeatability and 
day 2 to accomplish intermediate precision). As there is 
not a compendial standard available, the ratio between the 
practical concentration of the samples and the area-
response was used as response factor (RF). The relative 
standard deviation (RSD) of the RF values were 
evaluated. Accuracy was inferred after the establishment 




Solutions of 3-OBU and 3-OBB at working 
concentrations of 50 µg/mL were tested for 24, 48 and 72 
h at 25 ºC. The results were compared with those obtained 
with the freshly prepared solution. 
 
 
Results and discussion 
 
HPLC method development 
 
The proposed RP-LC method was optimized with the aim 
to develop a simple, rapid and suitable analytical method 
for separation, identification and quantitation of two new 
3-O-butanoyl derivatives of betulinic and ursolic acids 
with anti-malaric activity. Although CAD detection is not 
as common as UV-DAD, it was a valuable tool in mass 
balance investigation and might be as valuable in further 
studies with these two analytes, considering their low 
molar absorptivity. The developed LC-UV-CAD method 
demonstrated good selectivity and sensitivity to identify 
and quantify 3-OBB and 3-OBU in the presence of related 
molecules (BA and UA).  
The final chromatographic conditions established by the 
authors were selected after the robustness study, 
evaluating changes such as different batch column, flow 
rate (1.1 mL/min and 1.3 mL/min), pH of the aqueous 
phase (2.9 and 3.1) and mobile phase composition (83:17, 
v/v) and (87:13, v/v). Conditions were chosen based on 
peak performances (such as theoretical plates, capacity 
factor, tailing factor) and the best resolution between 
analytes. 
Different chromatographic systems were tested using 
different columns polarities and sizes. Separation between 
these similar structured acids, with adequate resolution, 
was possible with the use of a C18 250 x 4.6 mm, 5.0 μm 
column. The wavelength was defined by the evaluation of 




Recommended by the world health organization (WHO) 
and official compendia [24], mass balance demonstrated 
to be an accurate and reproducible methodology to assess 
the compound purities [25]. 
After purification, final purities of 94.56% and 83.38% 
were achieved, for 3-OBB and 3-OBU, respectively. 
Organic impurities were evaluated in UV and CAD, and 
the impurities with biggest areas (%) were considered to 
the mass balance. Chromatographic profile was different 
in both detectors, with an increased number of impurities 
detected by CAD, inferring the absence of chromophores 
in those impurities. Compound 3-OBU acid presented 
high profile of organic impurities, however, the purity of 
83.38% did not interfere with the identification and 
characterization of the compound, but further purification 
should be done to establish a reference standard. 























Total impurities Total purity 
3-OBB 0.01±0.0002% 5.10 ± 0.18% 0.32 ± 0.04% 5.43 ± 0.2202% 94.57 ± 0.2202% 
3-OBU 0.08 ±0.0009% 15.78 ± 1.21% 0.75 ± 0.06% 16.62 ± 1.9609 % 83.38 ± 1.9609%  
a Residue on ignition (USP 43); b HPLC-UV-CAD (same validated method was applied); c Loss on drying (USP 43). Data shown 






Selectivity of the method was demonstrated by adequate 
resolution among BA, UA, 3-OBB and 3-OBU (3.1 
between the synthesized compounds). Also, matrix 
components, impurities and the chromatographic system 
(e.g. diluent) did not interfere with 3-OBB and 3-OBU 
peaks (Fig. 2). Peak purity by UV-DAD detection was 
higher than 0.99 for both peaks. 
 
 
Figura 2. Chromatograms of diluent (A), betulinic acid (B) (peak 
1), ursolic acid (C) (peak 2), 3-OBB (D) (peak 3), 3-OBU (E) 
(peak 4) and a solution containing all compounds (F). 
 
Linearity, LOD and LOQ 
 
All calibration curves were linear in the range of 50 – 
150% of nominal concentration (25.0 to 75 µg/mL). The 
mean correlation coefficient (r) values were > 0.996 for 
both analytes. Linear regression was applied to confirm 
the method linearity, and, by residual analysis, it was 
verified the absence of atypical samples and the 
homoscedasticity of the residues. LOD was found to be 
0.92 µg/mL (UV) and 1.11 µg/mL (CAD) for 3-OBB; 
0.92 µg/mL (UV) and 1.16 µg/mL (CAD) for 3-OBU. 
LOQ was 2.81 µg/mL (UV) and 3.37 µg/mL (CAD) for 
3-OBB; 1.29 µg/mL (UV) and 3.50 µg/mL (CAD) for 3-
OBU. 
Linear regression equations and respective correlation 
coefficients are presented in table 2. 
 
Table 2.  Results of the linearity curves, equations and intercept 
deviation. 





UV 6009.8x - 20467 0.26 0.9978 
CAD 0.2496x + 0.1786 0.34 0.9983 
3-OBU 
UV 3975.3x – 4654.7 0.12 0.9981 
CAD 0.1355x – 0.3864 0.32 0.9958 
a Standard deviation of the Y-axis intercept (n = 3). 
 
Precision and accuracy 
 
Experimental data obtained from the repeatability and 
intermediate precision are shown in table 3. Values of 
intra and interday RSD were below 2.0% for 3-OBB and 
3-OBU in both UV and CAD.  
 
Table 3. Results of repeatability and intermediate precision of 3-
OBB and 3-OBU acids by UV and CAD. 
Compound UV CAD 
 Day 1 Day 2 Day 1 Day 2 
3-OBB 
Repeatability (µg/mL)a 50.0 50.5 50.0 50.5 
RF (µg/mL/A)b 5502.30 5563.30 0.2553 0.2553 
RSD %c 1.02 0.70 1.25 1.43 
Intermediate precision 
(µg/mL)d 
 50.2  50.2 
RF (µg/mL/A)  5532.80  0.2553 
RSD %  1.01  1.28 
3-OBU 
Repeatability (µg/mL)a 47.8 49.9 47.8 49.9 
RF (µg/mL/A)b 3494.39 3491.80 0.1291 0.1285 
RSD %c 1.07 1.10 1.13 1.11 
Intermediate precision 
(µg/mL)d 
 48.9  48.9 
RF (µg/mL/A)  3493.09  0.1288 
RSD %  1.04  1.10 
a Mean concentration of six replicates, b response factor; c 
relative standard deviation (%); d mean concentration of twelve 
replicates. 
 
As stated previously, in accordance with ICH, since there 
is no SQR available, accuracy was inferred after the 




The stability of 50.0 µg/mL solutions of 3-OBU and 3-
OBB acids were tested for 24, 48 and 72 h at room 
temperature. High stability (RSD < 2.0% in comparison 
with fresh solution) was observed under the tested 
condition in UV and CAD.  
 






The analytical method developed for the simultaneous 
analysis of antimalarials 3-O-butanoylbetulinic and 3-O-
butanoylursolic acids by RP-HPLC-UV-CAD 
demonstrated to be suitable for its purpose. This simple, 
robust and sensitive technique can be applied with 
reliability to identify and quantify these drug candidates 
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Melting range (FP 90, Mettler Toledo, Switzerland) 
 
Table 4. Melting range results for 3-OBB and 3-OBU 
compounds. 
Sample Melting range 
Melting range  
(n = 3) 
3-OBB 
313.5 °C – 350.8 °C 
312.9 °C – 351.0 °C 312.8 °C – 348.8 °C 
312.3 °C – 353.3 °C 
3-OBU 
255.9 °C – 284.5 °C 
256.3 °C – 283.2 °C 257.8 °C – 281.4 °C 




Differential scanning calorimetry (DSC-60, Shimadzu, Japan) 
 
 
Figure 3. Heating curve of 3-OBU obtained by DSC (10 °C/min). 
 
 










Nuclear magnetic resonance spectroscopy (NMR 1H and 13C) (DPX, Bruker, Germany) 
 
 
Figure 5. RMN 1H of 3-OBB (400 MHz, CDCl3). Hydrogens highlighted refer to the ones substituted in 3C. 
 
 
Figure 6. RMN 13C of 3-OBB (400 MHz, CDCl3). Carbons highlighted refer to the ones substituted in 3C. 
 
 
Figure 7. RMN 1H of 3-OBU (400 MHz, CDCl3). Hydrogens highlighted refer to the ones substituted in 3C. 
 
 





Figure 8. RMN 13C of 3-OBU (400 MHz, CDCl3). Carbons highlighted refer to the ones substituted in 3C. 
 
 









1 0.90 s – 3H CH3  
2 0.96 s – 3H CH3  
3 0.98 s – 6H CH3; CH3  
4 1.04 s – 3H CH3  
5 1.45 m – 2H CH2  
6 1.50 m – 1H  CH 
7 1.62 m – 2H CH2  
8 1.76 t – 1H CH  
9 1.80 s – 3H CH3  
10 2.04 m - 2H CH2  
11 2.24 t – 2H CH2  
12 2.31 m – 6H CH2; CH2; CH2 
13 3.14 t - 2H CH2 
14 4.53 dd – 1H CH  
15 4.64 s – 1H CH  






















Table 6. RMN 13C 1H of 3-OBB attributions. 
Position  (ppm) Attribution 
1 13.0 C 34 
2 15,0 C 27 
3 16.0 C 26 
4 16.5 C 25 
5 18.1 C 6 
6 18.6 C 33 
7 19.3 C 30 
8 20.8 C 11 
9 23.6 C 2 
10 25.6 C 12 
11 27.9 C 23; C 24 
12 29.7 C 15 
13 30.6 C 21 
14 32.1 C 16 
15 34.2 C 7 
16 36.7 C 22; C 32 
17 37 C 10 
18 37.1 C 4 
19 37.8 C 13 
20 38.4 C 1 
21 40.7 C 8 
22 42.4 C 14 
23 46.9 C 19 
24 49.3 C 18 
25 50.4 C 9 
26 55.4 C 17 
27 56.4 C 5 
28 80.6 C 3 
29 109.7 C 20 
30 150.3 C 29 
31 173.5 C 31 














Table 7. RMN 1H of 3-OBU attributions. 






1 0.70 s – 3H CH3  
2 0.84 s – 6H CH3  
3 0.87 s – 3H CH3  
4 0.92 s – 3H CH3  
5 1.00 s – 3H CH3  
6 1.05 d – 3H  CH3  
7 1.15 t – 3H CH3  
8 1.19 s – 3H CH3  
9 1.25 d – 3H CH3  
10 1.52 m - H CH  
11 1.73 m – 2H CH2  
12 1.77 m – 2H CH2 
13 1.80 m - H CH2  
14 1.96 dd – 2H CH2  
15 2.08 d - H CH  
16 2.23 t – 2H CH2  
17 2.39 s – 1H CH  
18 4.55 dd – 1H CH  
19 5.28 s – 1H CH  
 
Table 8. RMN 13C 1H of 3-OBU attributions. 
Position  (ppm) Attribution 
1 14.0 C 25 
2 15.3 C 27 
3 16.6 C 26 
4 16.9 C 29 
5 18.1 C 6 
6 21.6 C 30 
7 23.1 C 23; C 24 
8 25.8 C 11 
9 27.6 C 2 
10 27.7 C 16; C 33 
11 29.8 C 15 
12 31.5 C 21 
13 33.0 C 7; C 32; C 34 
14 33.8 C 22 
15 36.9 C 10 
16 37.7 C 4 
17 38.2 C 1 
18 38.8 C 19 
19 39 C 20 
20 39.5 C 8 
21 41.9 C 14 
22 47.3 C 9 
23 47.9 C 17 
24 52.5 C 18 
25 55.3 C 5 
26 80.5 C 3 
27 125.7 C 12 
28 138.4 C 13 
29 173.5 C 31 
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